Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM which is resistant to key antitumor drugs, first generatio...

Полное описание

Библиографические подробности

Главные авторы:	Aleksei Vladilenovich Petrov, D. V. Motorin, O. S. Pokrovskaya, E. S. Urnova, M. V. Nareiko, D. V. Babenetskaya, Yu. A. Alekseeva, L. L. Girshova, L. P. Mendeleeva, A. Yu. Zaritskii
Формат:	Artigo
Язык:	Russo
Опубликовано:	Practical Medicine Publishing House 2017-07-01
Серии:	Клиническая онкогематология
Предметы:	multiple myeloma “double-refractoriness” immunomodulating agents pomalidomide
Online-ссылка:	https://bloodjournal.ru/index.php/coh/article/view/440
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!